News & Events
【2023 ASH Breaking News】 LP-168 clinical data and LP-118 pre-clinical data first published at ASH 2023 as poster presentations
ASH Joint Program Committees have selected two LP-168 clinical abstracts in NHL and MCL, and one LP-118 preclinical study in MCL for poster presentations at the 65th ASH Annual Meeting and Exposition, December 9-12, 2023, in San Diego, California. LP-168 is a novel next generation BTK inhibitor, and LP-118 is a new generation dual Bcl-2/Bcl-xL inhibitor invented by Guangzhou Lupeng Pharmaceutical Co., Ltd.. Abstracts are available on the ASH website.
12 Dec 2023 04:39:00
【2023 ASH Breaking News】 Two LP-168 abstracts to be Reported as Oral Presentations
ASH Joint Program Committees have selected LP-168 preclinical and clinical abstracts for oral presentations at the 65th ASH Annual Meeting and Exposition, December 9-12, 2023, in San Diego, California. LP-168 is a novel next generation BTK inhibitor invented by Guangzhou Lupeng Pharmaceutical Co., Ltd.. Abstracts are available on the ASH website.
10 Dec 2023 08:24:00
【2023 ASH Breaking News】 LP-168 clinical data first published at ASH 2023 as poster presentations
ASH Joint Program Committees have selected two LP-168 clinical abstracts in NHL and MCL for poster presentations at the 65th ASH Annual Meeting and Exposition, December 9-12, 2023, in San Diego, California. LP-168 is a novel next generation BTK inhibitor invented by Guangzhou Lupeng Pharmaceutical Co., Ltd.. Abstracts are available on the ASH website.
10 Dec 2023 08:31:00
Clinical Trials Found
At Newave, we are committed to bring newest generation medicines to cancer patients worldwide. We are currently recruiting clinical trials across oncology and hematology areas
16 Mar 2022 08:13:00
JPM 2022: Newave Presented at the 40th Annual J.P. Morgan Healthcare Conference
Wednesday, January 12, 2022 (EST), Newave Pharmaceuticals presented at the 40th Annual J.P. Morgan Healthcare Conference.
13 Jan 2022 01:00:00